Dextran 40 IV IV Infusion
Dextran 40 10% + Dextrose 5%
Institute of Public Health
| Pack size | 500ml bag |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Dextran 40 IV IV Infusion is used for:
Thromboembolic disorders, Hypovolaemic shock, Pulmonary embolism, Venous thrombosis
Adult Dose
Intravenous
Thromboembolic disorders
Adult: As dextran 40: Initially, 500 ml of a 10% solution in glucose 5% infused over 4-6 hr, followed by 500 ml infused over 4-6 hr on the next and subsequent alternate days for not more than 10 days.
Prophylaxis of postoperative thromboembolic disorders
Adult: As dextran 40: 500 ml of a 10% solution in glucose 5% infused over 4-6 hr during or at the end of the surgery. Dose may be repeated the following day and treatment may be continued on alternate days for up to 10 days in high-risk patient.
Hypovolaemic shock
Adult: As dextran 40: Initially, 10 ml/kg given by rapid infusion as a 10% solution in glucose 5%. Doses may be given daily for up to 5 days.
Child Dose
Intravenous
Thromboembolic disorders
Child: As dextran 40: Up to 5 ml/kg in infants and 10 ml/kg in children.
Prophylaxis of postoperative thromboembolic disorders
Child: As dextran 40: Up to 10 ml/kg in children.
Renal Dose
Renal Impairment
Extreme caution
Administration
IV Administration
Infuse first 500 mL over 15-30 min, then slow infusion
Contra Indications
Hypersensitivity. Severe renal disease with oliguria or anuria. Marked cardiac decompensation. Pregnancy.
Precautions
Not a substitute for blood or blood components
Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young, elderly patients, or those with heart failure)
Large volumes of dextran (doses >1000 mL) may cause reduction in hemoglobin concentration and excessive dilution of plasma proteins due to hemodilution; transient prolongation of bleeding time or increase in bleeding tendency may occur with large volumes; use caution to prevent a decrease in hematocrit <30%.
Severe and fatal anaphylactoid reactions reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.
Use with caution in heart failure patients; monitor closely for fluid overload
Use with caution in patients with active hemorrhage; may increase risk of more bleeding
Renal failure reported with use; use with caution in patients with renal impairment; fluid status including urine output should be monitored closely; excessive dosing may precipitate renal failure in patients with advanced renal disease; use in severe oliguria or anuria is contraindicated
Use with caution in patients with thrombocytopenia; doses >1000 mL may interfere with platelet function and transiently prolong bleeding time; observe for bleeding
Pregnancy-Lactation
Interactions
Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine.
Adverse Effects
Side effects of Dextran 40 10% + Dextrose 5% :
Frequency Not Defined
Congestive heart failure
Mild hypotension
Tightness of chest
Thrombocytopenia
Anaphylaxis
Injection site infection/phlebitis
Acute renal failure
Acidosis (if NaCl soln used)
Pulmonary edema
Wheezing
Mechanism of Action
Dextrans produce expansion of plasma volume. It also reduces blood viscosity and inhibits sludging or aggregation of red blood cells.
Note
Dextran 40 IV IV Infusion manufactured by Institute of Public Health. Its generic name is Dextran 40 10% + Dextrose 5%. Dextran 40 IV is availble in Bangladesh.
Farmaco BD drug index information on Dextran 40 IV IV Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.